RNAC

Cartesian Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$6.36

Price (1 Year)

$10.59 $5.84

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %17.7 / %30
Non-compliant assets / Total market cap %42.9 / %30
Non-compliant revenue / Total income %97.7 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Website

Analysis (Turkish): RNAC Hissesi Caiz mi, Helal mi? Cartesian Therapeutics, Inc. Katılım Analizi